

Integrated Continuous Biomanufacturing III

An ECI Conference Series Volume 17AA

Cascais, Portugal
17-21 September 2017

Editors:

**Suzanne Farid
Paula Alves**

**Chetan Goudar
Veena Warikoo**

ISBN: 978-1-5108-5734-6

Printed from e-media with permission by:

Curran Associates, Inc.
57 Morehouse Lane
Red Hook, NY 12571



Some format issues inherent in the e-media version may also appear in this print version.

Copyright© (2017) by Engineering Conferences International
All rights reserved.

Printed by Curran Associates, Inc. (2018)

For permission requests, please contact Engineering Conferences International
at the address below.

Engineering Conferences International
32 Broadway, Suite 314
New York, NY 10004
USA

Phone: (212) 514-6760
Fax: (212) 514-6030

info@engconfintl.org

Additional copies of this publication are available from:

Curran Associates, Inc.
57 Morehouse Lane
Red Hook, NY 12571 USA
Phone: 845-758-0400
Fax: 845-758-2633
Email: curran@proceedings.com
Web: www.proceedings.com

Sunday, September 17, 2017

14:00 – 16:15 Conference Check-in

16:15 – 16:30 Welcome – Conference Chairs and ECI Liaison

16:30 – 17:15

Keynote Lecture 1

Are we prepared to meet the demands of a challenging, but promising future?1

James Thomas, Just Biotherapeutics, Inc. USA

17.15 – 17.45

Break

17:45 – 19:15

Workshops (2 in parallel)

Workshop 2: Evaluating Future Facility Design Concepts (XII+XIII)

Chairs: **Suzanne Farid**, University College London, United Kingdom

Michael Borys, Bristol-Myers Squibb, USA

Workshop 3: Gearing Up for Process Performance Qualification Readiness for ICB
(XV)

Chairs: **Mark Brower**, MSD, USA

Jeff Salm, Pfizer, USA

19:30 – 21:30

Dinner

21.30 – 23.00

Social Hour

Monday, September 18, 2017

07:30 – 09:00

Breakfast

Session 1: Continuous Culture to Capture

(Sponsored by Pfizer)

Chairs: **Martina Micheletti**, University College London (UCL), United Kingdom
Jason Walther, Sanofi, USA. **Thomas Ryll**, Immunogen, USA

09:00 – 09:25

Continuous bioprocessing for biologics manufacturing2

Weichang Zhou, WuXi Biologics, China

09:25 – 09:50

Development of highly intensified cell culture perfusion media and process with tremendous productivity potential, while having a low cell bleed requirement for maintaining an overall high yield3

Henry Lin, Boehringer Ingelheim, USA

09:50 – 10:15

Scalable technologies for process intensification in the continuous biomanufacturing factories of the future4

Gerben Zijlstra, Sartorius, Germany

10:15 – 10:40

Process development in screening scale bioreactors and perspectives for very high cell density perfusion16

Veronique Chotteau, KTH, Sweden

10:40 – 11:05

Evaluating options objectively – Resisting the "purist" approach to arrive at the most productive, robust, and practically implementable perfusion utilizing processes17

Gregory Hiller, Pfizer, Inc., USA

11:05 – 11:45

Coffee / Networking Break

11:45 – 12:30

Keynote Lecture 2

Systemic rejuvenation: From blood to molecular therapies18

Ludwig Aigner, Paracelsus Medical University Salzburg, Austria

12:30 – 13:45

Lunch

Session 2: Continuous Purification and Drug Product Sequences

(Sponsored by Amgen)

Chairs: **Manuel Carrondo**, iBET, Portugal
Art Hewig, Amgen, USA

13:45 – 14:10

Development of continuous production and purification processes for the integrated manufacture of monoclonal antibodies19

Massimo Morbidelli, ETH Zürich, Switzerland

14:10 – 14:35

From development to implementation with a fully integrated downstream bioprocess20

Jeff Salm, Pfizer, USA

14:35 – 15:00

Process intensification: Enabling technologies and methodologiesN/A

Jean-Marc Bielser / Jonathan Souquet, Merck KGaA, Switzerland

15:00 – 15:25

A disruptive alternative to semi-continuous multi-column chromatography (MCC) processes23

Michael Rose, UCB, United Kingdom

15:25 – 15:50

Multi-column chromatographic purification of influenza virus-like particles24

Ricardo Silva, iBET, Portugal

Monday, September 18, 2017 (continued)

15:50 – 16:45	<i>Coffee / Networking Break</i>
16:45 – 18:00	Poster Snapshot Session Chairs: Alois Jungbauer , BOKU, Austria Veronique Chotteau , KTH, Sweden Natalia Gomez , Amgen, USA Jarno Robin , Sanofi, France
16:45 – 16:50	Fouling mitigation in membrane based perfusion systems by oscillating tangential flow25 Maria Weinberger, Technical University of Munich, Germany
16:50 – 16:55	Bioprocess intensification and optimisation using macroscopic predictive models of cell culture processes27 Bassem Ben Yahia, UCB Pharma S.A., Belgium
16:55 – 17:00	Use of a biphasic perfusion process based on mild hypothermia for recombinant glucocerebrosidase (GBA) production30 Filipa Gonçalves, Instituto Superior Técnico, Portugal
17:00 – 17:05	Ultra scale-down mimics for perfusion culture: Experimental study for rapid biopharmaceutical process development34 Molly Tregidgo, University College London, United Kingdom
17:05 – 17:10	Evaluation of pseudo-perfusion feeding strategies for mAb production using a CHO cell line adapted to concentrated feed media36 Leda Castilho, Federal University of Rio de Janeiro, Brazil
17:10 – 17:15	Conversion of an industrial batch separation process to an autonomous integrated downstream process – A case study37 Anton Lofgren, Lund University, Sweden
17:15 – 17:20	Continuous protein precipitation – A robust antibody purification method without the need for steady state conditions during continuous integrated production.39 Daniel Burgstaller, University of Natural Resources and Life Sciences, Vienna, Austria
17:20 – 17:25	Continuous extraction strategies for monoclonal antibodies: From macro- to micro-scale40 Ana Margarida Azevedo, Instituto Superior Técnico, Portugal
17:25 – 17:30	Design of a novel continuous flow reactor for low pH viral inactivation41 Stephanie A. Parker, Keck Graduate Institute, USA
17:30 – 17:35	Supervisory control of integrated continuous downstream processes42 Bernt Nilsson, Lund University, Sweden
17:35 – 17:40	Digitalization platform and supervisory control of a continuous integrated bioprocess based on Raman spectroscopy44 Fabian Feidl, ETH Zürich, Switzerland
17:40 – 17:45	Up and down scale considerations for the continuous production of glycooptimized biopharmaceuticals45 Vicky Goralczyk, Glycotope GmbH, Germany
17:45 – 17:50	Scalable lentiviral vector production using stable producer cell lines in perfusion mode50 Aziza Manceur, National Research Council Canada, Canada

Monday, September 18, 2017 (continued)

- 17:50 – 17:55 **Continuous gas processing without bubbles using thin liquid film bioreactors containing biocomposite biocatalysts51**
Michael C. Flickinger, North Carolina State University, USA
- 17:55 – 18:00 **Enabling next-generation cell line development using continuous perfusion and nanofluidic technologies54**
Chetan Goudar, Amgen, USA
- 18:00 – 19:00 *Free Time*
- 19:00 – 20:30 *Dinner*
- 20:30 – 22:30 **Poster Session** with dessert and Social Hour

Tuesday, September 19, 2017

07:30 – 09:00

Breakfast

Session 3: End-to-end Continuous Biomanufacture
(Sponsored by Boehringer Ingelheim)

Chairs: **Massimo Morbidelli**, ETH Zurich, Switzerland
Rohan Patil, Sanofi, USA

09:00 – 09:25

Towards the implementation of a continuous bioprocess in single use technology55
Jorgen Magnus / Thomas Daszkowski, Bayer, Germany

09:25 – 09:50

Implementation of an end-to-end continuous bioprocessing platform using novel technologies56
Peter Levison, Pall Life Sciences, United Kingdom

09:50 – 10:15

Fully integrated continuous antibody processing demonstrates improved productivity57
Kenneth Lee, MedImmune LLC, USA

10:15 – 10:40

Balancing continuous, integrated, and batch processing58
Jonathan Coffman, Boehringer Ingelheim, USA

10:40 – 11:05

Continuous freeze-drying and its relevance to the pharma/biotech industry59
Roberto Pisano, Politecnico di Torino, Italy

11:05 – 11:45

Coffee / Networking Break

11:45 – 12:30

Keynote Lecture 3
Continuous manufacturing - EMA perspective and experience73
Nino Mihokovic, European Medicines Agency, United Kingdom

12:30 – 13:30

Lunch

13:30 – 15:00

Poster Session with dessert and Social Hour
Chairs: **Alois Jungbauer**, BOKU, Austria
Veronique Chotteau, KTH, Sweden
Natalia Gomez, Amgen, USA
Jarno Robin, Sanofi, France

15.00 – 22:00

Excursion and Dinner on your own before returning to hotel

Wednesday, September 20, 2017

07:30 – 09:00

Breakfast

Session 4: Predictive Continuous QbD Case Studies **(Sponsored by Sartorius Stedim Biotech)**

Chairs: **Naz Karim**, Texas A&M University, USA

Dorothee Ambrosius, Boehringer Ingelheim Pharma, Germany

09:00 – 09:25

Continuous bioprocessing and process analytical technologies: A path towards quality by design87

Nuno Pinto, Merck & Co., Inc., USA

09:25 – 09:50

Commercialization of a 2nd generation intensified perfusion process during life cycle management88

Jiuyi Lu, Sanofi, USA

09:50 – 10:15

Regulatory aspects of continuous downstream processing89

Marc Bisschops, Pall Corporation, Netherlands

10:15 – 10:40

Integrating analysis with process control for continuous bioprocessing: Extending the lifecycle concept to process analytical technologies90

Jose Menezes, Instituto Superior Tecnico & 4Tune Engineering Ltd, Portugal

10:40 – 11:05

A comprehensive study in PAT-applications for a QbD-compliant development of continuous biopharmaceutical production91

Reiner Luttmann, Hamburg University of Applied Sciences, Germany

11:05 – 11:45

Coffee / Networking Break

11:45 – 13.15

Workshops (2 in parallel)

Workshop 1: Increasing Speed to Clinic with Continuous Biomanufacture (XII+XIII)

Chairs: **Todd Przybycien**, Carnegie Mellon University, USA

Jon Coffman, Boehringer Ingelheim Pharma, USA

Workshop 4: Industry-Academia-Vendor-Government Collaboration in the ICB Space (XV)

Chairs: **Alessandro Butte**, ETH Zurich, Switzerland

Alex Xenopoulos, EMD Millipore, USA

13:15 – 14:30

Lunch

Session 5: Business Case for Facilities of the Future **(Sponsored by Merck)**

Chairs: **Alex Kiparissides / Nigel Titchener-Hooker**, University College London (UCL), United Kingdom

Thomas Sauer, Sanofi, Germany

14:30 – 14:55

Delivering a toolbox of flexible platforms for clinical and commercial bioprocessing production: 'Defining the business drivers for development and implementation'92

Mark Brower, Merck & Co Inc, USA

14:55 – 15:20

Are integrated processes a solution looking for a problem to solve, or a tool to solve the problem?107

Joseph Shultz, Novartis Pharma AG, Switzerland

15:20 – 15:45

Process economics in biologics manufacturing108

John Machulski, Sanofi, USA

Wednesday, September 20, 2017 (continued)

15:45 – 16:10 **Next generation manufacturing for biologics: Integration of a hybrid model for continuous manufacturing concepts into a clinical facility109**
Michael Borys, Bristol-Myers Squibb, USA

16:10 – 16:30 *Coffee / Networking Break*

Session 6: Continuous Biomanufacture Beyond CHO or Proteins
(Sponsored by GE Healthcare)

Chairs: **Chris Love**, Massachusetts Institute of Technology, USA
Uwe Gottschalk, Lonza, Switzerland

16:30 – 16:55 **Beyond CHO – Non-mammalian hosts could be the future expression systems of choice for recombinant biotherapeutics110**
Chapman Wright, Biogen, USA

16:55 – 17:20 **Integrated manufacturing with microbial hosts for fast process development and production111**
J. Christopher Love, Massachusetts Institute of Technology, USA

17:20 – 17:45 **Continuous biomanufacturing concepts for cell therapy processes112**
Erika M. McAfee, Lonza Walkersville, Inc., USA

17:45 – 18:10 **Bioprocess intensification for the continuous expansion of 3D human induced pluripotent stem cell aggregates in bioreactors113**
Bernardo Abecasis, IBET, Portugal

18:10 – 18:25 *Stretch Break*

18:25 – 19:00 **Keynote Lecture 4 (ICB Award Lecture)**
Development and large scale manufacturing of exosome-based therapeutics114
Konstantin Konstantinov, Codiak Biosciences, USA

19:00 – 19:45 *Free Time*

19:45 – 20:30 *Reception*

20:30 – 22:30 *Conference Banquet and Awards*

22.30 – 23.30 *Social Hour*

Thursday, September 21, 2017

07:00 – 09:30 Breakfast and departures

Poster Presentations

Continuous Culture to Capture

1. **Optimizing media for perfusion combining predictive scale-down models and multivariate approaches128**
Jochen Sieck, Merck KGaA, Germany
2. **Development of a scale down toolbox for perfusion process development130**
Jean-Marc Bielser, Merck KGaA, Switzerland
3. **Development and application of screening scale bioreactor systems for very high cell density perfusion of mammalian cells132**
Caijuan Zhan, KTH - Cell Technology Group (CETEG), Sweden
4. **Fouling mitigation in membrane based perfusion systems by oscillating tangential flow135**
Maria Weinberger, Technical University of Munich, Germany
5. **Bioprocess intensification and optimisation using macroscopic predictive models of cell culture processes137**
Bassem Ben Yahia, UCB Pharma S.A., Belgium
6. **Ultra scale-down mimics for perfusion culture: Experimental study for rapid biopharmaceutical process development140**
Molly Tregidgo, University College London, United Kingdom
7. **Evaluation of pseudo-perfusion feeding strategies for mAb production using a CHO cell line adapted to concentrated feed media142**
Leda Castilho, Federal University of Rio de Janeiro, Brazil
8. **Use of a biphasic perfusion process based on mild hypothermia for recombinant glucocerebrosidase (GBA) production143**
Filipa Gonçalves, Instituto Superior Técnico, Portugal
9. **Enhancing crispr-mediated CHO cell antibody productivity through concentrated fed-batch or continuous perfusion145**
Ching-Jen Yang, Development Center for Biotechnology, Taiwan
10. **Evaluation of cell culture with a simulated continuous manufacturing (sCM) process in 50mL tubespins for clone selection146**
Natalia Gomez, Amgen, USA
11. **Screening cell growth in simulated continuous manufacturing spin tubes determines optimal media conditions for cell lines147**
Jonathan Lull, Amgen, USA
12. **Development of a novel automated perfusion mini bioreactor 'ambr® 250 perfusion'148**
Barney Zoro, Sartorius Royston, United Kingdom
13. **More than 15 years of continuous processing using chemostat cultures. A Shire niche?149**
Daniel Fleischanderl, Shire, Austria
14. **Small-scale development and optimization of stirred tank mammalian cell perfusion cultures150**
Moritz Wolf, ETH Zurich, Switzerland

15. **Intensification of a multi-product perfusion platform through medium and process development151**
Shawn Barrett, Sanofi, USA
16. **Computational Fluid Dynamics (CFD) modelling and experimental confirmation of hollow fiber tangential flow filtration (HFTFF) and alternating tangential flow filtration (ATF) In a perfusion bioreactor152**
Flaka Radoniqi, Keck Graduate Institute and Boehringer Ingelheim, USA
17. **Up and down scale considerations for the continuous production of glycooptimized biopharmaceuticals153**
Vicky Goralczyk, Glycotope GmbH, Germany
18. **Ultra scale-down concepts to address early stage process development challenges in integrated continuous bioprocessing158**
Andrea Rayat, University College London, United Kingdom

Continuous Purification and Drug Product Sequences

19. **Continuous protein precipitation – A robust antibody purification method without the need for steady state conditions during continuous integrated production159**
Daniel Burgstaller, University of Natural Resources and Life Sciences, Vienna, Austria
20. **Continuous in-line virus inactivation for next generation bioprocessing160**
Melissa Holstein, MilliporeSigma, USA
21. **Consideration of filter design space for validation of virus filtration in continuous processing applications161**
Nigel Jackson, Pall Life Sciences, United Kingdom
22. **Impact of product and recycle times in MCSGP polishing on charge variant separation162**
Sebastian Vogg, ETH Zurich, Switzerland
23. **Novel single-column simulated moving-bed chromatography platform for quasi-continuous biopurification163**
José P. B. Mota, LAQV-REQUIMTE, FCT-UNL, Portugal
24. **Design of a novel continuous flow reactor for low pH viral inactivation164**
Stephanie A. Parker, Keck Graduate Institute, USA
25. **Progress towards continuous aqueous two-phase extraction via TAPPIR165**
Andreas Bommarius, Georgia Institute of Technology, USA
26. **Continuous extraction strategies for monoclonal antibodies: From macro- to micro-scale166**
Ana Margarida Azevedo, Instituto Superior Técnico, Portugal
27. **Enabling end-to-end continuous biomanufacturing by exploring integration approaches of continuous TFF167**
Eva Udovic, University of Ljubljana, Slovenia
28. **Viral clearance considerations for continuous viral inactivation168**
Raquel Orozco, Boehringer Ingelheim, USA

29. **Conversion of an industrial batch separation process to an autonomous integrated downstream process – A case study169**
Anton Lofgren, Lund University, Sweden
30. **Much-efficient and cost-effective manufacturing of antibody biotherapeutics employing integrated negative chromatography technology171**
Razwan Hanif, UCB, United Kingdom
31. **A fully continuous downstream process concept without column chromatography172**
Todd Przybycien, Carnegie Mellon University, USA
32. **Dynamic process control of twin-column periodic countercurrent chromatography processes173**
Thomas Muller-Spath, ETH Zurich, Switzerland

End-to-end Continuous Biomanufacture

33. **Application of single pass TFF to enable intensified and continuous biological manufacturing174**
Herbert Lutz, MilliporeSigma, USA
34. **Development of an N-1 perfusion process and optimized scale-down models for implementation in a platform CHO cell culture manufacturing process176**
Frank V. Ritacco, Bristol-Myers Squibb, USA
35. **Process considerations for Protein A affinity capture, virus inactivation, and linked polishing steps in multi-column continuous purification of monoclonal antibodies177**
Robert Mierendorf, Semba Biosciences, Inc., USA
36. **Continuous purification of monoclonal antibody using periodic counter-current chromatography179**
Wei-Kuang Chi, Development Center for Biotechnology, Taiwan
37. **Clarification and capture of a CHO-derived monoclonal antibody through flocculation and AEX processes180**
Rimenys J. Carvalho/Leda Castilho, Federal University of Rio de Janeiro (UFRJ), COPPE, Brazil

Predictive Continuous QbD Case Studies

38. **Supervisory control of integrated continuous downstream processes182**
Bernt Nilsson, Lund University, Sweden
39. **Process analytical technologies for a continuous capture and connected downstream process184**
Nina Brestrich/Joseph Shultz, Novartis Pharma AG, Switzerland
40. **Digitalization platform and supervisory control of a continuous integrated bioprocess based on raman spectroscopy185**
Fabian Feidl, ETH Zürich, Switzerland
41. **Process analytical technology (PAT) in continuous bioprocessing186**
Edita Botonjic-Sehic, Pall Life Sciences, USA

- 42. **Qualification of single use in-line sensors for use in continuous bioprocessing188**
James Furey, PendoTECH, USA
- 43. **Time-series datamining for continuous bioprocess analysis190**
Yang Yang, University College London, United Kingdom
- 44. **Enhancing multivariate calibration model reproducibility for the online monitoring of upstream processes in continuous biomanufacturing191**
Nicholas A. Trunfio, University of Massachusetts - Lowell, U.S. Food and Drug Administration, USA
- 45. **FDA/OBP laboratory research to support continuous bioprocessing192**
Scott Lute, U.S. FDA, CDER/OBP, USA

Business Case for Facilities of the Future

- 46. **Cost modeling of an integrated, continuous downstream mAb platform193**
Mark Schofield, Pall Life Sciences, USA
- 47. **Facility design concepts for adoptive T-cell immunotherapy195**
Tania Pereira Chilima, UCL, United Kingdom

Continuous Biomanufacture Beyond CHO or Proteins

- 48. **Continuous desalting of refolding solution by ion exchange chromatography196**
Nicole Walch, Austrian Centre of Industrial Biotechnology, Austria
- 49. **Continuous gas processing without bubbles using thin liquid film bioreactors containing biocomposite biocatalysts197**
Michael C. Flickinger, North Carolina State University, USA
- 50. **Novel concepts for efficient and predictable membrane separation in continuous cell retention and downstream processing200**
Ulrich Kulozik, Technical University of Munich, Germany
- 51. **Stirred tanks in cascades and plug-flow tubular bioreactors for continuous production of viral vaccines202**
Felipe Tapia, Max Planck Institute for Dynamics of Complex Technical Systems, Germany
- 52. **Scalable lentiviral vector production using stable producer cell lines in perfusion mode203**
Aziza Manceur, National Research Council Canada, Canada
- 53. **Continuous chromatography beyond affinity capture of monoclonal antibodies204**
Linda Mathiasson, GE Healthcare, Sweden
- 54. **Enabling next-generation cell line development using continuous perfusion and nanofluidic technologies205**
Chetan Goudar, Amgen, USA